Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInvestment IncomeNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Fresenius Medical Care AG (FMS) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Fresenius Medical Care AG (FMS) over the last 16 years, with Dec 2024 value amounting to $15.6 billion.

  • Fresenius Medical Care AG's Cost of Revenue rose 7.29% to $4.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 billion, marking a year-over-year increase of 4.19%. This contributed to the annual value of $15.6 billion for FY2024, which is 0.87% down from last year.
  • Latest data reveals that Fresenius Medical Care AG reported Cost of Revenue of $15.6 billion as of FY2024, which was down 0.87% from $15.7 billion recorded in FY2023.
  • Fresenius Medical Care AG's Cost of Revenue's 5-year high stood at $15.7 billion during FY2023, with a 5-year trough of $14.1 billion in FY2020.
  • Moreover, its 3-year median value for Cost of Revenue was $15.6 billion (2024), whereas its average is $15.5 billion.
  • Its Cost of Revenue has fluctuated over the past 5 years, first grew by 8.05% in 2021, then dropped by 0.87% in 2024.
  • Fresenius Medical Care AG's Cost of Revenue (MRY) stood at $14.1 billion in 2020, then increased by 8.05% to $15.2 billion in 2021, then increased by 0.56% to $15.3 billion in 2022, then grew by 2.81% to $15.7 billion in 2023, then decreased by 0.87% to $15.6 billion in 2024.
  • Its Cost of Revenue was $15.6 billion in FY2024, compared to $15.7 billion in FY2023 and $15.3 billion in FY2022.